These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10974501)

  • 1. Proton magnetic resonance spectroscopy of patients with parkinsonism.
    Abe K; Terakawa H; Takanashi M; Watanabe Y; Tanaka H; Fujita N; Hirabuki N; Yanagihara T
    Brain Res Bull; 2000 Aug; 52(6):589-95. PubMed ID: 10974501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton magnetic resonance spectroscopy (1H MRS) in patients with sporadic cerebellar degeneration.
    Terakawa H; Abe K; Watanabe Y; Nakamura M; Fujita N; Hirabuki N; Yanagihara T
    J Neuroimaging; 1999 Apr; 9(2):72-7. PubMed ID: 10208103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes.
    Federico F; Simone IL; Lucivero V; Mezzapesa DM; de Mari M; Lamberti P; Petruzzellis M; Ferrari E
    Ital J Neurol Sci; 1999 Aug; 20(4):223-9. PubMed ID: 10551908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
    Federico F; Simone IL; Lucivero V; Iliceto G; De Mari M; Giannini P; Mezzapesa DM; Tarantino A; Lamberti P
    Mov Disord; 1997 Nov; 12(6):903-9. PubMed ID: 9399213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.
    Watanabe H; Fukatsu H; Katsuno M; Sugiura M; Hamada K; Okada Y; Hirayama M; Ishigaki T; Sobue G
    J Neurol Neurosurg Psychiatry; 2004 Jan; 75(1):103-9. PubMed ID: 14707317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
    Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
    Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
    J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes.
    Zanigni S; Testa C; Calandra-Buonaura G; Sambati L; Guarino M; Gabellini A; Evangelisti S; Cortelli P; Lodi R; Tonon C
    Parkinsonism Relat Disord; 2015 Aug; 21(8):929-37. PubMed ID: 26077167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
    Tedeschi G; Litvan I; Bonavita S; Bertolino A; Lundbom N; Patronas NJ; Hallett M
    Brain; 1997 Sep; 120 ( Pt 9)():1541-52. PubMed ID: 9313638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
    Juh R; Kim J; Moon D; Choe B; Suh T
    Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
    Federico F; Simone IL; Lucivero V; De Mari M; Giannini P; Iliceto G; Mezzapesa DM; Lamberti P
    J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):239-42. PubMed ID: 9069478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes.
    Clarke CE; Lowry M
    Eur J Neurol; 2001 Nov; 8(6):573-7. PubMed ID: 11784341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies.
    Kaasinen V; Kankare T; Joutsa J; Vahlberg T
    J Nucl Med; 2019 Dec; 60(12):1757-1763. PubMed ID: 30979821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal metabolic networks in atypical parkinsonism.
    Eckert T; Tang C; Ma Y; Brown N; Lin T; Frucht S; Feigin A; Eidelberg D
    Mov Disord; 2008 Apr; 23(5):727-33. PubMed ID: 18186116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
    Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
    Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction.
    Tanaka Y; Obata T; Sassa T; Yoshitome E; Asai Y; Ikehira H; Suhara T; Okubo Y; Nishikawa T
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):365-72. PubMed ID: 16732755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism.
    Yoon WT
    Neurol Neurochir Pol; 2018; 52(1):48-53. PubMed ID: 29196058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD.
    Yekhlef F; Ballan G; Macia F; Delmer O; Sourgen C; Tison F
    J Neural Transm (Vienna); 2003 Feb; 110(2):151-69. PubMed ID: 12589575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
    Ellis CM; Lemmens G; Williams SC; Simmons A; Dawson J; Leigh PN; Chaudhuri KR
    Neurology; 1997 Aug; 49(2):438-44. PubMed ID: 9270574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.